Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiagnoCure Oncology Laboratories has announced that it will introduce its new Previstage GCC, a molecular diagnostic test for the staging of colorectal cancer, at the American Society of Clinical Oncology Annual Meeting on May 30-June 3, 2008 in Chicago, Illinois.
Subscribe to our email newsletter
The Previstage guanylyl cyclase C (GCC) test employs qRT-PCR technology, which has been shown to be up to 100,000-times more sensitive than traditional histopathology in detecting occult metastases. The technology can detect one cancer cell in up to 10 million cells, versus one in 200 normal cells with traditional methods.
According to the company, the Previstage GCC test will provide clinicians a significantly more sensitive tool than traditional histopathology review alone for staging a patient with colorectal cancer and therefore may help the physician determine the most appropriate course of treatment.
With the Previstage GCC test, a positive result would be an indication of lymph node metastases and would be consistent with a patient having Stage III disease.